ANTIBODY THERAPEUTICS XCHANGE
EUROPE 2022
Zurich, November 22

Welcome to hubXchange’s Europe Antibody Therapeutics Xchange 2022, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing antibody therapeutics, through a series of roundtable discussions.
Discussion topics will cover Target Selection, Lead Identification & Optimization, Formats & Scaffolds, Bi/Multi-Specifics and Emerging Technologies.
Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.

Please note this is an In-Person meeting.

VENUE DETAILS: Hilton Zurich Airport Hotel, Hohenbuehlstrasse 10 – 8152 Opfikon, Switzerland

Target Selection

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Address & Keynote: Writing the Future of Biologics with Synthetic DNA and Machine Learning

Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody discovery libraries including highly diverse, synthetic, naïve antibody phage display libraries and target class specific antibody phage display libraries against difficult-to-drug targets. Here, Radha will cover:

How Twist goes from DNA to Antibody Discovery
How we currently identify a clinical candidate from sequence space
A proof-of-concept case study where NGS and an ML based approach were used to identify leads

Radha Parmar

Science and Technology Consultant (STC) Biologics – UK AND IRELAND,

Twist Bioscience

Radha is the Science and Technology Consultant for TWIST EMEA and a Subject Matter Expert in the area of Antibodies. Prior to Twist, Radha led the Antibody Engineering team within Biopharm Discovery at GSK and was a Program Leader taking antibody discovery projects from target validation through to candidate selection. Through her work at Twist, her interests now include synthetic biology, protein evolution, variant library generation as well as antibody discovery, optimisation and production.

9:05 – 10:05

Considerations and challenges guiding target selection in the development of antibody-based therapeutics

Methodologies for antibody target discovery and validation
What kind of unique target requirements do the different derivatives of the monoclonal Ab format have (e.g. bispecific antibodies, antibody-drug conjugates, other antibody-derived fusion proteins)
Discussing the use of next gen in silico technologies in target identification and validation for antibody-based therapeutics

Martin Steegmaier

Chief Scientific Officer, SOTIO

Martin Steegmaier graduated from the Northern Arizona University. He earned his Ph.D. in biochemistry from the University of Basel, Switzerland. In addition, Martin received an MBA from the Edinburgh Business School (UK). He complemented his scientific training by spending 4 years as a postdoctoral fellow at Stanford University Medical School. In 2000, Martin joined Boehringer Ingelheim’s Oncology Drug Discovery Department and held positions with increasing responsibility advancing first-in-class oncology projects into the clinic. Martin joined Roche in 2006 in Basel and held various positions in Pharma Partnering and in the Oncology disease area. In 2012, Martin became the Head of Discovery for the Large Molecule Research organization at the Roche Innovation Center Munich site with the responsibility to generate and profile novel therapeutic antibodies for different disease areas. In March 2020, Martin became Head of Research at MorphoSys in Planegg Munich, Germany focusing on the generation of differentiated, more efficacious and safer antibody-based therapeutics in the area of immuno-oncology and hematology-oncology. Martin Steegmaier joined SOTIO Biotech in September 2022 as Chief Scientific Officer.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning refreshments

11:20 – 12:20

Hidden in plain sight – Target discovery in African ancestry genomes

Understanding the value of ethnically diverse patient samples for target identification and drug discovery
Diversifying patient stratification to enhance clinical outcomes within drug development

Justin Devine

Chief Medical Officer & interim Chief Scientific Officer, Synexa

Justin is a medical doctor, immunologist and pharmacologist and a co-founder and CMO of Synexa. His primary focus is to understand our clients’ objectives in new drug development and to implement biomarker strategies that bring real insight to the challenges of clinical development and the immunological underpinning of health and disease.

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation: Selection of clinically relevant VHH antibodies via cell-based phage display selection and characterizations

Early valuable selection of potential therapeutic antibodies on native, cell-expressed target by VHH-phage display technology
Genetic immunization of llama’s has high potential for successful Ab discovery against membrane proteins
Deselecting antibodies out of lead candidate pool by benchmarking the antibodies against IPA’s library of clinical antibodies with known developability profiles.

Debby Kruijsen

General Manager, ImmunoPrecise Antibodies

Dr. Debby Kruijsen is the General Manager of IPA (ImmunoPrecise Antibodies) Europe. Dr. Kruijsen obtained her PhD in immunology at Utrecht University in the Netherlands. In 2012, she joined IPA where she held different scientific and management positions until becoming General Manager. In addition to overseeing IPA Europe’s operations, Dr. Kruijsen works closely with the executive and global teams to develop and execute business strategies, improve operational efficiencies, and support IPA as an innovative company in the CRO space.

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

15:00 – 15:30

Poster Session: Pioneer: A novel, very large therapeutic antibody library

The Pioneer library is one of the largest functional phage display Fab libraries ever made. Our extensive experience in phage display resulted in a superior library for the generation of therapeutic lead candidates. Pioneer takes advantage of a novel selection system. We will introduce the Pioneer library and the SpyDisplay selection system and will show data for antibody selection and characterization.

Katharina Reefschläger

Technical Sales Specialist Custom Antibodies, Bio-Rad

Katharina Reefschläger is a technical sales specialist for Bio-Rad´s therapeutic antibody discovery services. She has been with Bio-Rad in various sales related positions for over 10 years. Prior to this she worked in a genetic diagnostic lab as scientific customer support for more than 2 years. Katharina holds a diploma in Biology from Julius-Maximilians-University Würzburg/Germany and a PhD in Biology from Ludwig-Maximilians-University Munich/Germany.

15:30– 15:45

Afternoon refreshments

15:45-16:45

How to gain the full potential out of the emerging pipeline of cancer therapies

How to identify effective combinations among the growing pipeline of CPIs, immunocytokines, ADCs, bi-specifics, cancer vaccines, etc.
How to predict efficacy or translate preclinical findings
How to assess tox/safety of novel combinations
How to identify biomarkers (patient selection, PD)

Johan Lantto

Sr Director, Portfolio Management, Symphogen

Johan Lantto is a Sr Director, Portfolio Management at Symphogen, a Servier company based in Denmark. Johan holds a Ph.D. in Immunotechnology from Lund University, Sweden, where he studied antibody evolution and repertoire development, and he has more than 20 years of experience with antibody engineering and the development of therapeutic antibodies. For the past 18 years, Johan has worked for Symphogen where he has been involved in the development of the company’s Symplex™ antibody discovery platform as well as been responsible for antibody drug discovery and development projects within infectious disease and oncology. Johan has been responsible for six oncology projects that have been brought to the clinic by Symphogen.

17:50-18:50

Canape/Drinks Reception

Lead Identification & Optimization

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Address & Keynote: Writing the Future of Biologics with Synthetic DNA and Machine Learning

How Twist goes from DNA to Antibody Discovery
How we currently identify a clinical candidate from sequence space
A proof-of-concept case study where NGS and an ML based approach were used to identify leads

Radha Parmar

Science and Technology Consultant (STC) Biologics – UK AND IRELAND,

Twist Bioscience

9:05 – 10:05

Antibody discovery platform: strengths, weaknesses and trends

What are the (unexpected) strengths and weaknesses of different antibody discovery platforms?
What are the most challenging bottlenecks in current antibody discovery platforms? Which of them seem addressable and how?
Which parameters (cost, time, diversity, number of hits, affinity, developability, biology, species, etc) influence the choice of antibody discovery platform to be used?
Which platforms are mature, which ones still have potential for optimization? Which platforms will (still) be in use in 10, 20 or 30 years from now?

Andreas Loos

Director of Biologics Discovery ChemPartner

Andreas Loos, PhD, has joined ChemPartner in 2021 as Director of Biologics Discovery and he currently
leads the Biologics Discovery Team at ChemPartner’s South San Francisco site. The team was one of the
first adopters of BLI’s Beacon technology and successfully uses the platform since 2019 to conduct antibody discovery projects. Prior to joining ChemPartner, Andreas has led an antibody discovery and assay development group at Aridis Pharmaceuticals. During his PhD and post-doctoral training in Gent
(Belgium), Heidelberg (Germany) and Vienna (Austria), he studied production and post-translational
modifications of biologics in plants.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Antibody Optimisation: Choosing the right platform for developability

Developability criteria of antibodies and protein therapeutics: What are they?
When is the right time to assess developability?
The benefits and risks of upfront prediction compared to empirical determination of developability profiles.
How to get out of a developability problem.

Radha Parmar

Science and Technology Consultant (STC) Biologics – UK AND IRELAND,

Twist Bioscience

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation: Selection of clinically relevant VHH antibodies via cell-based phage display selection and characterizations

Early valuable selection of potential therapeutic antibodies on native, cell-expressed target by VHH-phage display technology
Genetic immunization of llama’s has high potential for successful Ab discovery against membrane proteins
Deselecting antibodies out of lead candidate pool by benchmarking the antibodies against IPA’s library of clinical antibodies with known developability profiles.

Debby Kruijsen

General Manager, ImmunoPrecise Antibodies

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

15:30 – 15:45

Afternoon refreshments

15:45 16:45

Lead optimization beyond affinity: What are the next challenges and how to address them successfully?

What are lead optimization parameters beyond affinity for biologics that protein engineers are currently facing?
How to approach these parameters and what are the bottlenecks?
What is the impact of in silico (e.g. machine learning) approaches or new HTS methods?

Ernst Weber

Head of Molecular Design & Engineering, Bayer AG

Ernst Weber, Ph.D., is Head of Molecular Design & Engineering in the department of Antibody Lead Discovery and Optimization at Bayer AG. After receiving his Ph.D. in Biochemistry from the University of Halle (Germany), he conducted his Postdoc work as EMBO fellow at the MRC-LMB in Cambridge focusing on protein engineering. In 2008 he joined ICON Genetics where he developed new HTS compatible molecular biology technologies applicable to the optimization of single proteins but also complete enzymatic pathways. 2012 he moved to Bayer AG and is here responsible for antibody optimization and as project leader in multiple indications. Since 2016 he led the setup of Bayer’s bispecific antibody platform.

16:50 – 17:50

Preclinical development of antibody leads with complex biology/MoA

What are the considerations for antagonist versus agonistic mAbs
How can we define function in the selection/screening of mAb hits
Pitfalls to be aware of when considering biological activity of pre-clinical leads

Matthew Lambert

Director, Pfizer

Matthew Lambert is the Director of BioMedicine Design (BMD) in Dublin, Ireland. His group is responsible for the optimisation of lead molecules and the discovery of novel drugs in the pre-Clinical space. Within Pfizer, BMD feeds the “large molecule” portfolio and Matthew’s group contribute to this goal largely through the use of display technologies, such as yeast and phage display. Matthew has over 15 years’ experience in the pharmaceutical industry. He has authored numerous publications in the field and is a named inventor on several patents. His group has successfully advanced several drugs from initial discovery to FIH studies.

17:50– 18:50

Canape/Drinks Reception

Formats & Scaffolds

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Address & Keynote: Writing the Future of Biologics with Synthetic DNA and Machine Learning

How Twist goes from DNA to Antibody Discovery
How we currently identify a clinical candidate from sequence space
A proof-of-concept case study where NGS and an ML based approach were used to identify leads

Radha Parmar

Science and Technology Consultant (STC) Biologics – UK AND IRELAND,

Twist Bioscience

9:05 – 10:05

Strategies for the design and generation of multi-functional biologics

Antibody building blocks
How to choose the right format
Developability

Klaus Koefoed

Director, Antibody Technology, Symphogen

Klaus Koefoed is Scientific Director, Antibody Technology Innovation at Symphogen, a Servier company. His
research focuses on generation of recombinant antibody repertoires from immunized material using Symplex single B cell technology and NGS. Ab engineering to achieve novel MOA and incorporation of antibody building blocks into multi-specifics for functional screening in format. Klaus has worked in the antibody field for more than 25 years within all stages of early antibody generation and characterization. He received his PhD in Immunology from the University of Copenhagen and did his Postdoctoral training at University of California, San Francisco (UCSF).

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Including proteins in antibody discovery with polyclonal antibody sequencing:

When conventional antibody discovery techniques fail, what do you do?
Can your library of polyclonal antibody reagents be the fuel for your next discovery campaign?
Can you complement your existing programs with serum proteomics?

Anthony Stajduhar

Director, International Business Development, Rapid Novor

Anthony has been heading the business development at Rapid Novor for nearly 6 years, merging his previous 8 years of experience in the business roles with a strong passion for biomedical research, stemming from his training in biomedical engineering. His current efforts are focused on the growth of the REpAb™, HDX-MS epitope mapping, and SPR Kinetic analysis solutions with pharmaceutical and biotech companies globally. His partnerships are focused on using REpAb in patients or animal models to sequence monoclonal antibodies from polyclonal sera, as well as immune system profiling using NovorIg, the team’s NGS based analysis to monitor the relative quantity of specific antibodies over time. Anthony’s a hobby farmer and an ongoing researcher of biotech business in his spare time.

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation: Selection of clinically relevant VHH antibodies via cell-based phage display selection and characterizations

Early valuable selection of potential therapeutic antibodies on native, cell-expressed target by VHH-phage display technology
Genetic immunization of llama’s has high potential for successful Ab discovery against membrane proteins
Deselecting antibodies out of lead candidate pool by benchmarking the antibodies against IPA’s library of clinical antibodies with known developability profiles.

Debby Kruijsen

General Manager, ImmunoPrecise Antibodies

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

15:30 – 15:45

Afternoon Refreshments

17:50– 18:50

Canape/Drinks Reception

Bi/Multi-Specifics

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Address & Keynote: Writing the Future of Biologics with Synthetic DNA and Machine Learning

How Twist goes from DNA to Antibody Discovery
How we currently identify a clinical candidate from sequence space
A proof-of-concept case study where NGS and an ML based approach were used to identify leads

Radha Parmar

Science and Technology Consultant (STC) Biologics – UK AND IRELAND, Twist Bioscience

9:05 – 10:05

Bi/tri-specific strategies for overcoming cell engager toxicity

Use of multiple targets to increase specificity against tumour cells
Use of multiple targets for enhancing activity of effector cells against tumours
Cytotoxicity associated with T cell or NK cell engagement
The role of affinity/kinetics in promoting proper cell engagement

Gustavo Schmidt Moreira

Head of Antibody and Protein Biochemistry, Tacalyx GmbH

Gustavo Schmidt Moreira was born in the Southern part of Brazil, where he concluded his Bachelor’s and Master’s degree in Biotechnology. He completed his PhD in 2019 at TU Braunschweig, Germany, in the field of Antibody Engineering and Phage Display. Currently, he works as Head of Antibody and Protein Biochemistry at Tacalyx GmbH, a Max Planck Institute spin-off start-up company located in Berlin, which is focused on the discovery and development of monoclonal antibodies for cancer therapy using Tumor-Associated Carbohydrate Antigens (TACA) produced with exclusive technologies.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Early immunogenicity risk assessment tools for traditional and multi-specific therapeutics

In silico and in vitro immunogenicity assessment, test early to avoid surprises later on
The power of combined tools
Challenges with Immunogenicity testing of multi-specifics

Sofie Pattijn

Chief Technology Officer & Founder, ImmunXperts

Sofie has over 25 years of experience in the field of immunogenicity assessment (vaccines and biotherapeutics) and in vitro assay development with a focus on functional assays for immunogenicity, immune oncology and Cell and Gene Therapy products. She has extensive hands-on lab experience and has managed and coached several In Vitro teams over the last decade. From 2008 till 2013 she was Head of the In Vitro Immunogenicity group at AlgoNomics (Ghent, Belgium) and Lonza Applied Protein Services (Cambridge, UK). Prior to that, she worked at Innogenetics, Belgium for over 15 years.

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation: Selection of clinically relevant VHH antibodies via cell-based phage display selection and characterizations

Early valuable selection of potential therapeutic antibodies on native, cell-expressed target by VHH-phage display technology
Genetic immunization of llama’s has high potential for successful Ab discovery against membrane proteins
Deselecting antibodies out of lead candidate pool by benchmarking the antibodies against IPA’s library of clinical antibodies with known developability profiles.

Debby Kruijsen

General Manager, ImmunoPrecise Antibodies

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

15:00 – 15:30

Poster Session: Comparing potential bispecific formats of trastuzumab and a humanized OKT3

Not every antibody can be combined to produce well-behaved multi-specifics. The valency and geometry of each design can determine the production, target engagement and ultimately the requisite biological functions. In this case study, we selected two established antibody therapeutics, trastuzumab and a humanized OKT3 to produce 20 different bispecific formats to compare the feasibility of each format.

Donmienne Leung

Head, Protein Engineering, Absolute Antibody

Donmienne is a pharma veteran with 15+ years of experience in biologics research. She co-authored 11 granted patents including 5 clinical molecules and 20+ publications. After her PhD in chemistry from the University of Queensland, she pursued post-doctoral training in chemical biology at the Scripps Research Institute. Prior to joining Absolute Antibody, she was a senior research advisor at Eli Lilly where she led and delivered molecules into the pipeline.

15:30 – 15:45

Afternoon Refreshments

15:45 – 16:45

Novel applications for bispecific antibody strategies

Are some bsAbs formats more suitable for certain indications?
What bsAb strategies are needed for treatment of solid tumors?
What other challenges limit the applications for bsAbs?

Laura von Schantz

VP Discovery, Alligator Biosciences

Laura von Schantz is VP Discovery at Alligator Bioscience. With the firm believe that biotech companies in the field of immuno-oncology must invest in establishing strong technologies and advantageous translational processes to be able to generate compounds at a competitive pace, Laura has established a platform at Alligator that allows for fast generation of bispecific drug candidates with excellent properties in respect to function, manufacturability and stability. Laura is trained in antibody engineering as well as project management and corporate strategy. Laura holds a PhD in immunotechnology from the University of Lund.

16:50– 17:50

Developability assessment and challenges for multispecific antibodies and proteins:

What are the developability challenges for multispecific proteins?
How to assess the developability of multispecific proteins?
What can we learn from:
Molecules on the market? Molecules in development? Our experience? Is there a general strategy?

Jörg Thomas Regula

Head of Early Stage Analytics, Boehringer Ingelheim

Joerg holds a PhD in Biochemistry and has been working for more than 20 years in small and large pharmaceutical companies in research and early development of biotherapeutics.

The initial focus of his work was mass spectrometry and later at Roche and Sanofi, it expanded to protein analytics including potency testing. Developability assessment and protein engineering are
fields of high personal interest. Besides this Joerg was driving the CMC development of different bispecific antibodies as early project leader. At iOmx Therapeutics AG Joerg was heading the CMC Development and currently at Boehringer Ingelheim he is working as CMC expert supporting internal
biologics projects and assessing external opportunities.

17:50– 18:50

Canape/Drinks Reception

Emerging Technologies

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Address & Keynote: Writing the Future of Biologics with Synthetic DNA and Machine Learning

How Twist goes from DNA to Antibody Discovery
How we currently identify a clinical candidate from sequence space
A proof-of-concept case study where NGS and an ML based approach were used to identify leads

Radha Parmar

Science and Technology Consultant (STC) Biologics – UK AND IRELAND,

Twist Bioscience

9:05 – 10:05

Beyond flow cytometry – non-traditional methods for investigating functional properties for antibody-target interaction

What are the limitations of state-of-the-art flow cytometry for functional profiling?
Will microfluidic based or similar technologies for single cell functional analysis be general applicable for antibody functional assessment during screening or profiling?
Can we and what is the value for applying advanced iPSC model in combination with
HTP single cell analysis of transcriptome for antibody discovery

Allan Jensen

Vice President, Biotherapeutic Discovery, Lundbeck

Dr Allan Jensen is an expert in discovery and preclinical development of antibody based drugs and has several years of experience from various positions in the biotech and pharmaceutical industry. Allan holds M.Sc. and Ph.D. degrees in Molecular
Biology from University of Aarhus. He entered the field of antibody discovery about two decades ago by joining Symphogen, continued his career at Pfizer and currently holds a position at Lundbeck as Vice President, Biotherapeutic Discovery. He has provided significant scientific input to technologies supporting antibody discovery and preclinical development.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Novel antibody discovery and development technologies

What are the main challenges of generating optimal antibody candidates for immunotherapy?
How can we address these challenges in different discovery and development steps with established and novel technologies?
Where do novel technologies really help us to develop better antibody drugs?

Thomas Schirrmann

COO, YUMAB GmbH

Thomas Schirrmann is biochemist by training and holds an PhD in immunology. He worked for more than 20 years in research with focus on recombinant antibody technologies and immunotherapies including CAR-NK, bispecifics and antibody fusion proteins. He published >80 scientific publications and is inventor of several patents. He founded several biotech companies including the antibody platform company YUMAB in Braunschweig, Germany (12/2012), which he manages as CEO since then. In 2020, he spun-out CORAT Therapeutics, which brought its anti-COVD-19 lead program COR-101 in 11 months from target to the clinics.

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation: Selection of clinically relevant VHH antibodies via cell-based phage display selection and characterizations

Early valuable selection of potential therapeutic antibodies on native, cell-expressed target by VHH-phage display technology
Genetic immunization of llama’s has high potential for successful Ab discovery against membrane proteins
Deselecting antibodies out of lead candidate pool by benchmarking the antibodies against IPA’s library of clinical antibodies with known developability profiles

Debby Kruijsen

General Manager, ImmunoPrecise Antibodies

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

15:30 – 15:45

Afternoon Refreshments

15:45 – 16:45

Emerging Technologies You Can Use in the Antibody Field

Sharing our experiences on what is working and not and discuss the maturity of some Emerging Technologies
New digital solutions that can accelerate your work and how to leverage them in your day to day operations
Computational complexity of existing methods and what to do if you are not a software engineer or a tech person

Fausto Artico

Global R&D Tech Head, Director of Innovation & Data Science, GlaxoSmithKline

Fausto has a double PhD (Information Technology and Computer Science), earning his second master’s and PhD at the University of California – Irvine. He has worked in multi-disciplinary teams and has over 20 years of experience in academia and industry. As a Physicist, Mathematician, Engineer, Computer Scientist, and HPC and Data Science expert, Fausto has worked on key projects at European and American government institutions and with key individuals, like Nobel Prize winner Michael J. Prather. After his time at NVIDIA corporation in Silicon Valley, Fausto worked at the IBM T J Watson Center in New York and now at GSK.

16:50 – 17:50

Novel approaches to optimize protein formulations and enhance developability of biotech products

Protein drug product formulations are traditionally developed based on platform approaches and knowledge of scientists. More complex molecules (e.g., next-gen antibody formats like di/tri-specifics) at higher concentration (e.g., ≥150 mg/mL) in patient-friendly devices require novel approaches to optimize faster and with reduced resources their stability over a commercially viable shelf-life.

Do we have efficient alternative approaches for a toolbox to design an “optimal” protein formulation and ensure manufacturability?
In-silico modeling/computer aided prediction (credibility, regulations-policies)?
Use of machine-learning algorithms (case studies)?
Microfluidics/automated experimental approaches to assess protein stability?

Klaus Wuchner

Scientific Director, Analytical Development, Janssen Pharmaceutical

Klaus Wuchner has over 20 years’ experience in pharmaceutical R&D with focus on analytical development. Currently, he holds a position as Scientific Director within the global BioTherapeutics Development & Supply organization at Janssen R&D, Schaffhausen, Switzerland. His general areas of responsibility cover strategic, regulatory, and scientific direction for analytical development of large molecule drug products. He highly appreciates collaboration within multi-industry groups with leading and participating in workstreams within e.g., EFPIA/MQEG, BioPhorum, and IQ International Consortium. He holds a Ph.D in analytical chemistry of the “Institut National Polytechnique of Toulouse”, France.

17:50– 18:50

Canape/Drinks Reception

ANTIBODY THERAPEUTICS XCHANGE EUROPE 2022 Zurich, November 22

Target Selection

Partners

ANTIBODY THERAPEUTICS XCHANGE
EUROPE 2022
Zurich, November 22